NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Fingolimod for the treatment of relapsing-remitting multiple sclerosis Response to consultee and commentator comments on the matrix of consultees and commentators

	Version of matrix of consultees and commentators reviewed: Provisional matrix of consultees and commentators sent for consultation					
Sum	Summary of comments, action taken, and justification of action:					
	Proposal:	Proposal made by:		Action taken: Removed/Added/Not included/Noted	Justification:	
1.	Remove Age Concern England from patient/carer group consultees.	Age Concern		Removed	Completed as per the specific organisations request.	
2.	Remove British Ethnic Health Awareness Foundation (BEHAF) from patient/carer group consultees.	NICE Secretariat		Removed	British Ethnic Health Awareness Foundation (BEHAF) has been removed from the Charity Commission records and therefore doesn't meet the inclusion criteria.	

National Institute for Health and Clinical Excellence

Consultation comments on the matrix for the technology appraisal of fingolimod for the treatment of relapsing-remitting multiple sclerosis Issue date: June 2010

3.	Remove Confederation of Indian Organisations from patient/carer group consultees.	NICE Secretariat	Removed	Confederation of Indian Organisations have now closed, and therefore been removed from the matrix.
4.	Remove Help the Aged from patient/carer group consultees.	Help the Aged	Removed	Completed as per the specific organisations request.
5.	Remove Age Concern Cymru from patient/carer group consultees.	Age Concern	Removed	Completed as per the specific organisations request.
6.	Add Commissioning Support Appraisals Service to general group commentators.	NICE Secretariat	Added	Commissioning Support Appraisals Service meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a general commentator.
7.	Add Scottish Medicines Consortium to general group commentators.	NICE Secretariat	Added	Scottish Medicines Consortium meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a general commentator.

National Institute for Health and Clinical Excellence Consultation comments on the matrix for the technology appraisal of fingolimod for the treatment of relapsing-remitting multiple sclerosis Issue date: June 2010

8.	Add MRC Clinical Trials Unit to relevant research group commentators.	NICE Secretariat	Added	MRC Clinical Trials Unit meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a relevant research group commentator.
9.	Remove United Kingdom Clinical Research Network from relevant research group commentators.	NICE Secretariat	Removed	The United Kingdom Clinical Research Network is a part of the National Institute for Health Research. As per inclusion criteria an organisation is listed only once therefore they have been removed from the matrix.
10.	Add Connect to patient/carer group consultees.	NICE Secretariat	Added	Connect meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a patient/carer group consultee.
11.	Add Multiple Sclerosis National Therapy Centres to patient/carer group consultees.	NICE Secretariat	Added	Multiple Sclerosis National Therapy Centres meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a patient/carer group consultee.
12.	Add Neurosupport to patient/carer group consultees.	NICE Secretariat	Added	Neurosupport meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a patient/carer group consultee.

National Institute for Health and Clinical Excellence Consultation comments on the matrix for the technology appraisal of fingolimod for the treatment of relapsing-remitting multiple sclerosis Issue date: June 2010

13.	Please note that the UK MS Specialist Nurses Association (MSSNA) need to be added as a professional group.	Merck Serono and Novartis	Added	UK MS Specialist Nurses Association (MSSNA) meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a professional group consultee.
14.	Sanofi-aventis will not be involved with glatiramer acetate in the UK after 01Dec10 when responsibility for the product reverts exclusively to Teva Pharmaceuticals Ltd.	Teva	Noted	Comment Noted
15.	Thank you very much for sending this to the Chartered Society of Physiotherapy but we do not feel that this particular technology appraisal is relevant for us to comment on.	Chartered Society of Physiotherapy	Removed	Removed as per specific organisation's request.
16.	British Neurological Society was on a similar matrix (Cladribine for the treatment of relapsing- remitting multiple sclerosis)	NICE Secretariat	Noted	The British Neurological Society was a spelling error and should actually be the Neuropathalogical Society.

National Institute for Health and Clinical Excellence Consultation comments on the matrix for the technology appraisal of fingolimod for the treatment of relapsing-remitting multiple sclerosis Issue date: June 2010